Monoclonal Antibodies Market Is Predicted To Reach USD 138.6 Billion By 2024:By Grand View Research, Inc.
The global monoclonal antibodies (mAbs) market was valued at
USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion
by 2024. Increasing R&D pertaining to the development of therapeutic mAbs
coupled with supportive government initiatives is expected to drive the
monoclonal antibodies market growth over the forecast period.
Increasing demand for personalized
medicine is a vital factor responsible for the increasing development of
therapeutic antibodies to provide targeted therapies as every individual
responds in a different manner to a particular treatment. Moreover, related
benefits of using mAbs for therapeutic purposes, including fewer adverse
effects, homogeneity, specificity, and large-scale production, are contributing
toward significant market growth.
In addition, the government
initiatives to enable cost-effective production of mAbs is anticipated to
propel the emergence of this sector over the forecast period. For instance, the
biomanufacturing initiative byNational Institute of Standards and Technology in
the U.S. provides scientifically sound regulatory guidelines to ensure
effective and safe manufacturing of protein therapeutics and to support
biopharmaceutical manufacturers in offering low-cost and high-quality protein
drugs across the globe.
Browse full research report on Monoclonal
Antibodies Market: http://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
Further Key Findings from the
Study Suggest:
- Human-based
mAbs segment is predicted to grow at a lucrative CAGR in the coming years
due to their associated benefits and numerous R&D activities conducted
for further development of human mAbs. Large number of mAbs of human
origin are in phase III clinical trial for cancer treatment
- In
vitro production of mAbs is anticipated to show the fastest growth owing
to its wide-scale adoption by biologics manufacturers due to its greater
efficiency in cost and time
- The
research institute segment is anticipated to exhibit profitable growth due
to increasing R&D efforts in the biotech industry as monoclonal
antibodies have emerged as a major class of therapeutics for several human
diseases, particularly immunological infectious diseases and cancer
- The
Asia pacific region has significant growth potential due to rising
government initiatives in this region supporting the use of mAbs for
research and treatment purposes coupled with the surge in sponsored
R&D projects for the development of cost-effective therapeutic mAbs.
- For
instance, government-led fund providers, such as National Natural Science
Foundation and National Basic Research Program of China, offer
financial support to enterprises and universities to conduct mAb research
and development.
- The
key players serving the monoclonal antibodies market arePfizer, Inc.,
GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc.,
Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V.,
Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson
& Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc.,
Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
- The
introduction of advanced methods for mAb production further encourages the
pharmaceutical companies to build their own product pipeline. According to
a study published by NCBI at the end of 2013, approximately 816 companies
were involved in therapeutic protein research.
Browse more reports of this
category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented
the monoclonal antibodies market by source type, production, indication,
end-use, and region:
Global Monoclonal
Antibodies Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
- Murine
- Chimeric
- Humanized
- Human
Global Monoclonal
Antibodies Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
- In
Vivo
- In
Vitro
Global Monoclonal
Antibodies Indication Outlook (Revenue, USD Billion, 2013 - 2024)
- Cancer
- Autoimmune
Diseases
- Inflammatory
Diseases
- Infectious
Diseases
- Microbial
Diseases
- Others
Global Monoclonal
Antibodies End-use Outlook (Revenue, USD Billion, 2013 - 2024)
- Hospitals
- Research
Institutes
- Others
Monoclonal antibodies Market
Regional Outlook (Market Revenue in USD Billion, 2013 - 2024)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- Middle
East and Africa
- South
Africa
Access press release of this
research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
For more information: www.grandviewresearch.com
Comments
Post a Comment